$OXIS Files Form 8-K

ITEM 8.01 Other Events-Licensing of Assets by SubsidiaryThe Registrants wholly owned subsidiary Oxis Biotech, Inc., a Delaware corporation, executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma and initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun(Sean)Xie. The license agreement provides Oxis Biotech, Inc an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma. Dr. Xie joins Oxis Biotech as a consultant and member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech, Inc.

Sean Xie, MD, PhD, EMBA (one of the world’s foremost cannabinoid research scientists) is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. Xie is a charter member of the NIH BPNS Study Section Review Panel, an oversea expert reviewer for the Chinese Natural Science Foundation, ad hoc reviewer for the Netherlands Organizations for Scientific Research Council for Chemical Sciences, MCMB Foundation for MRC UK, and the Wellcome Trust Fund, Sir Henry Wellcome Fellowship, London, UK. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. He was an invited international Assessment Panelist for Fudan University College of Pharmacy, a member of the Board of Directors of the Chinese Association of Professionals in Science and Technology, and a Chair of the CAPST Biomedical and Pharmaceutical Society. Dr. Xie also holds adjunct professor title in top institutes and colleges of pharmacy in China, including CAMS Tianjin Institute of Hematology Stem Cell Medical Center; Fudan, Shanghai Jiaotong, and Zhejiang Universities. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.